Analysts are suggesting that GlaxoSmithKline is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis to prop up its dividend, Reuters reports.
GlaxoSmithKline CEO Andrew Witty recently said slow-starting respiratory newcomer Breo was finally gaining some market traction. And now, it has a new asthma indication the company hopes can help speed things along.
GlaxoSmithKline has shone in a ranking of the social media savvy of the 100 largest publicly traded firms in the United Kingdom. The Big Pharma ranked second on the list, an outcome that suggests at least some drugmakers compare favorably to their peers in other industries.
GlaxoSmithKline needed to jump-start sluggish sales of its respiratory newcomers Breo and Anoro after early uptake fell short of expectations. Now a targeted DTC push may be charging up sales.
Zostavax is the only shingles vaccine approved in the U.S. and the EU, but GlaxoSmithKline is one step closer to changing that. On Tuesday, the British pharma announced Phase III results for its shingles candidate, HZ/su, reporting an overall efficacy of 97.2% compared with placebo.
In a Phase III trial involving 15,000 children in Africa, early results showed that children who received three doses of GlaxoSmithKline's candidate malaria vaccine were half as likely to contract malaria infection in the year after vaccination. But results reported Friday in The Lancet showed a significant decline in the level of protection after four years.
GlaxoSmithKline's in-development shingles vaccine successfully staved off the virus in a massive Phase III study--and, in contrast with its top competitor, the shot's effects didn't wane among elderly patients.
After urging price concessions for pneumococcal disease vaccines in January and receiving a 20-cent-per-dose discount from Pfizer, Médecins Sans Frontières is sure to be unhappy with GlaxoSmithKline's response.
A little more than a month after completing its big asset swap with GlaxoSmithKline, Novartis CEO Joe Jimenez says he's going back to the bargaining table to look for some bolt-on buyouts in the $2 billion to $5 billion range.
Novartis beat profit estimates for the first quarter, partly because of the big deal closing with GlaxoSmithKline March 2. Now, CEO Joe Jimenez says the Swiss drugmaker is back on the dealmaking trail.